GenFleet Tightens Board Nomination Rules to Strengthen Governance

GenFleet Therapeutics has updated its Board Nomination Committee terms to enhance governance, effective March 24, 2026. The committee, primarily composed of independent non-executive directors, will oversee board structure, succession planning, and diversity policy. Responsibilities include annual reviews of board size and skills, director selection criteria, and performance assessments. The committee can seek independent advice, aiming for transparent oversight and alignment with corporate governance standards in Hong Kong. GenFleet, a biopharmaceutical company listed in Hong Kong, focuses on innovative therapeutics and adheres to local listing rules and corporate law.